Repurposing of Hdac Inhibitors Toward Anti-Hepatitis C Virus Drug Discovery: Teaching an Old Dog New Tricks

References

• Hézode C , AsselahT, ReddyKRet al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet385 (9986), 2502–2509 (2015).
   PubMed Web of Science ®Google Scholar
• Afdhal N , ReddyKR, NelsonDRet al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med.370 (16), 1483–1493 (2014).
   PubMed Web of Science ®Google Scholar
• Shirakawa K , ChavezL, HakreS, CalvaneseV, VerdinE. Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol.21 (6), 277–285 (2013).
   PubMed Web of Science ®Google Scholar
• Xing S , SilicianoRF. Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov. Today18 (11–12), 541–551 (2013).
   PubMed Web of Science ®Google Scholar
• Siliciano JD , SilicianoRF. Recent developments in the search for a cure for HIV-1 infection: targeting the latent reservoir for HIV-1. J. Allergy Clin. Immun.134 (1), 12–19 (2014).
   PubMed Web of Science ®Google Scholar
• Bruner KM , HosmaneNN, SilicianoRF. Towards an HIV-1 cure: measuring the latent reservoir. Trends Microbiol.23 (4), 192–203 (2015).
   PubMed Web of Science ®Google Scholar
• Lusic M , GiaccaM. Regulation of HIV-1 latency by chromatin structure and nuclear architecture. J. Mol. Biol.427 (3), 688–694 (2015).
   PubMed Web of Science ®Google Scholar
• Campbell GR , BruckmanRS, ChuYL, SpectorSA. Autophagy induction by histone deacetylase inhibitors inhibits HIV type 1. J. Biol. Chem.290 (8), 5028–5040 (2015).
   PubMed Web of Science ®Google Scholar
• Miura K , TauraK, KodamaY, SchnablB, BrennerDA. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology48 (5), 1420–1429 (2008).
   PubMed Web of Science ®Google Scholar
• Liu H , TrinhTL, DongH, KeithR, NelsonD, LiuC. Iron regulator hepcidin exhibits antiviral activity against hepatitis C virus. PLoS ONE7 (10), e46631 (2012).
   PubMed Web of Science ®Google Scholar
• Horl WH , SchmidtA. Low hepcidin triggers hepatic iron accumulation in patients with hepatitis C. Nephrol. Dial. Transpl.29 (6), 1141–1144 (2014).
   PubMed Web of Science ®Google Scholar
• López-Rodríguez R , Hernández-BartoloméÁ, BorqueMJet al. Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy. Genes Immun.14 (5), 317–324 (2013).
   PubMed Web of Science ®Google Scholar
• Sato A , SaitoY, SugiyamaKet al. Suppressive effect of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) on hepatitis C virus replication. J. Cell. Biochem.114 (9), 1987–1996 (2013).
   PubMed Web of Science ®Google Scholar
• Kozlov MV , KleymenovaAA, RomanovaLIet al. Benzohydroxamic acids as potent and selective anti-HCV agents. Bioorg. Med. Chem. Lett.23 (21), 5936–5940 (2013).
   PubMed Web of Science ®Google Scholar
• Kozlov MV , KleymenovaAA, KonduktorovKA, MalikovaAZ, KochetkovSN. Selective inhibitor of histone deacetylase 6 (tubastatin A) suppresses proliferation of hepatitis C virus replicon in culture of human hepatocytes. Biochemistry (Mosc.)79 (7), 637–642 (2014).
   PubMed Web of Science ®Google Scholar
• Kozlov MV , KleymenovaAA, RomanovaLIet al. Pyridine hydroxamic acids are specific anti-HCV agents affecting HDAC6. Bioorg. Med. Chem. Lett.25 (11), 2382–2385 (2015).
   PubMed Web of Science ®Google Scholar
• Kovacs JJ , MurphyPJM, GaillardSet al. HDAC6 Regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell18 (5), 601–607 (2005).
   PubMed Web of Science ®Google Scholar
• Parmigiani RB , XuWS, Venta-PerezGet al. HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc. Natl Acad. Sci. USA105 (28), 9633–9638 (2008).
   PubMed Web of Science ®Google Scholar
• Ai T , XuY, QiuL, GeraghtyRJ, ChenL. Hydroxamic acids block replication of hepatitis C virus. J. Med. Chem.58 (2), 785–800 (2015).
   PubMed Web of Science ®Google Scholar
• Song Y , ChenW, KangDet al. “Old friends in new guise”: exploiting privileged structures for scaffold re-evolution/refining. Comb. Chem. High Throughput Screen.17 (6), 536–553 (2014).
   PubMed Web of Science ®Google Scholar
• Li X , ZhanP, LiuHet al. Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors. Bioorg. Med. Chem.20 (18), 5527–5536 (2012).
   PubMed Web of Science ®Google Scholar
• Song Y , LinX, KangDet al. Discovery and characterization of novel imidazopyridine derivative CHEQ-2 as a potent CDC25 inhibitor and promising anticancer drug candidate. Eur. J. Med. Chem.82, 293–307 (2014).
   PubMed Web of Science ®Google Scholar
• Raju TN . The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918–99), and George H Hitchings (1905–98). Lancet355, 1022 (2000).
   PubMedGoogle Scholar
• Song Y , ZhanP, LiuX. Heterocycle-thioacetic acid motif: a privileged molecular scaffold with potent, broad-ranging pharmacological activities. Curr. Pharm. Design19 (40), 7141–7154 (2013).
   PubMed Web of Science ®Google Scholar
• Song Y , ZhanP, ZhangQ, LiuX. Privileged scaffolds or promiscuous binders: a glance of pyrrolo[2,1-f][1,2,4]triazines and related bridgehead nitrogen heterocycles in medicinal chemistry. Curr. Pharm. Design19 (8), 1528–1548 (2013).
   PubMed Web of Science ®Google Scholar